Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Räth U, Hohnloser J, Clemm C, Berdel W, Siegert W, et al. Bokemeyer C, et al. Among authors: berdel w. Eur J Cancer. 1993;29A(16):2225-31. doi: 10.1016/0959-8049(93)90211-w. Eur J Cancer. 1993. PMID: 8110490 Clinical Trial.
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Räth U, Siegert W, et al. Harstrick A, et al. Among authors: berdel w. J Cancer Res Clin Oncol. 1991;117 Suppl 4:S198-202. doi: 10.1007/BF01613227. J Cancer Res Clin Oncol. 1991. PMID: 1665492 Clinical Trial.
Single-agent carboplatinum for advanced seminoma. A phase II study.
Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schöber C, Wilke H, Poliwoda H. Schmoll HJ, et al. Among authors: berdel we. Cancer. 1993 Jul 1;72(1):237-43. doi: 10.1002/1097-0142(19930701)72:1<237::aid-cncr2820720142>3.0.co;2-l. Cancer. 1993. PMID: 8508413 Clinical Trial.
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W. Rick O, et al. Among authors: berdel we. J Clin Oncol. 2001 Jan 1;19(1):81-8. doi: 10.1200/JCO.2001.19.1.81. J Clin Oncol. 2001. PMID: 11134198 Clinical Trial.
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group. Schmoll HJ, et al. Among authors: berdel we. J Clin Oncol. 2003 Nov 15;21(22):4083-91. doi: 10.1200/JCO.2003.09.035. Epub 2003 Oct 20. J Clin Oncol. 2003. PMID: 14568987 Clinical Trial.
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. van den Berg H, et al. Eur J Cancer. 2015 Nov;51(16):2453-64. doi: 10.1016/j.ejca.2015.06.123. Epub 2015 Aug 10. Eur J Cancer. 2015. PMID: 26271204 Clinical Trial.
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kührer I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ. Bokemeyer C, et al. Among authors: berdel we. Semin Oncol. 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8. Semin Oncol. 1998. PMID: 9578059 Review.
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W. Zander AR, et al. Among authors: berdel we. Ann Oncol. 2008 Jun;19(6):1082-9. doi: 10.1093/annonc/mdn023. Epub 2008 Feb 27. Ann Oncol. 2008. PMID: 18304964 Free article. Clinical Trial.
680 results